SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm

LOS ANGELES--()--Lundin Law PC announces a class action lawsuit has been filed against Juno Therapeutics Inc. ("Juno" or the "Company") (Nasdaq: JUNO) concerning possible violations of federal securities laws between June 4, 2016 and July 7, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the September 12, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here to participate. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Juno failed to disclose that a patient died during a clinical trial for its product candidate in May 2016. Juno was thus trading at artificially inflated prices and some insiders participated in heavy selling of shares until July 7, 2016. On July 7, 2016 the Company announced the May 2016 death and two additional deaths during clinical trial, and the Food and Drug Administration put a hold on the trial. After the release of this news, shares of Juno dropped in value significantly.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125

Lundin Law PC